Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.
Ublituximab shows five year relapse reduction and disability benefits in multiple sclerosis, supporting early high efficacy ...
Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage ...
The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for ...
Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous system, ...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient ...
Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results